Sjögren's research encompasses vital topics such as the causes, subtypes, biomarkers, genetics, antibodies, and progression.
Current and Emerging Evidence for Toll-Like Receptor (TLR) Activation in Sjögren's Syndrome (SS). Therapies that target TLR signaling cascades will likely reduce both exocrine-specific and systemic manifestations of SS. PubMed, J Immunol Res, 2018 Dec 20;2018:1246818.
Expression of interleukin-17 in primary Sjögren's syndrome (pSS) and the correlation with disease severity: A systematic review and meta–analysis. The expression of IL-17 is obviously increased in patients with pSS, especially among those without immunosuppressive treatment. PubMed, Scand J Immunol, 2018 Apr;87(4):e12649. (Also see Interleukins)
Deterioration in saliva quality in patients with Sjögren's syndrome (SS): impact of decrease in salivary epidermal growth factor on the severity of intraoral manifestations. The deterioration in saliva quality as well as lower intraoral clearance by hyposalivation could play a role in the pathogenesis of refractory intraoral manifestations in patients with SS. PubMed, Inflamm Regen, 2018 Apr 9;38:6.
Association between memory B–cells and clinical and immunological features of primary Sjögren's syndrome (pSS) and Sicca patients. It remains to be clarified whether Sicca patients with decreased memory B–cells represent pSS and if B–cell profiling could help in the diagnosis of pSS. PubMed, Rheumatol Int, 04/06/2018.
B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome. All biomarkers were associated with total EULAR Sjögren's Syndrome Disease Activity Index scores but with differing domain associations. PubMed, Rheumatology (Oxford), 03/28/2018. (Also see B cells and T cells)
Genetics in Sjögren's Syndrome. The genes associated with Sjögren syndrome (SS) can be assigned to the NF–kB pathway, the IFN signaling pathway, lymphocyte signaling, and antigen presentation. Rheumatic Disease Clinics, 06/21/2016.
Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus (SLE) and Sjögren's syndrome (pSS). Functional LILRA3 is a new susceptibility factor for SLE and pSS and it highly predisposes to certain phenotypes such as leucopenia, thrombocytopenia and autoantibody-positive subphenotypes. PubMed, Ann Rheum Dis. (Also see Research on Systemic Lupus Erythematosus)
Novel and rare functional genomic variants in multiple autoimmune syndrome (MAS) and Sjögren's syndrome. The LRP1/STAT6 novel mutation has the strongest case for being categorised as potentially causative of MAS given the presence of intriguing patterns of functional interaction with other major genes shaping autoimmunity. PubMed, J Transl Med. (Also see Multiple Autoimmune Syndrome)
Etiopathogenic Role of Surfactant Protein D (SP-D) in the Clinical and Immunological Expression of Primary Sjögren Syndrome (pSS). High SP-D levels were found with severe glandular involvement, hypergammaglobulinemia, leukopenia, extraglandular manifestations, and positive anti-Ro/La antibodies. PubMed, J Rheumatol.
Sjögren's Antibodies (Anti-SS-A/Anti-SS-B). SS-A(Ro) is found in 60% to 70% of patients with Sjögren's syndrome and 30% to 40% of patients with SLE. SS-B(La) is found in 50% to 60% of Sjögren's syndrome and 10% to 15% of SLE. LabCorp.
In Loving Memory of Lorraine Wempner, a donation to tackle scleroderma has been made by Paul Wempner. Posted 11/13/2019. (Also see: ISN News)
We have the world's best supporters! See ISN News.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: